Information Provided By: 
Fly News Breaks for September 20, 2018
ACAD
Sep 20, 2018 | 15:01 EDT
After the FDA announced that it has concluded there is no new risk associated with Nuplazid, Cowen analyst Ritu Baral said she thinks the FDA's statement will go a long way in easing patient safety concerns. The analyst, who sees the FDA news as "very likely" to boost Nuplazid back to growth soon, keeps an Outperform rating on Acadia shares.
News For ACAD From the Last 2 Days
There are no results for your query ACAD
